Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 361 - 372 of 441

EASL Studio S1 E3: The EASL-Lancet Liver Commission

Description

In this third episode of the EASL Studio, the experts will be tackling the EASL – Lancet Liver Commission on liver diseases in Europe. How do we reduce inequity in Europe? How do we improve awareness and education? How can we put a stop to stigmatisation of patients with liver diseases?

Time Title
00:00-02:59

Welcome and introduction on the EASL-Lancet Liver Commission

Tom Hemming Karlsen, University of Oslo, Norway
02:59-12:00

Part 1: Primary care focus - The importance of building stronger bridges between primary and secondary care

Rachel Pryke, United Kingdom
12:00-22:54

Part 2: Stigma and discrimination

Patrizia Carrieri, INSERM, SESSTIM, France
22:54-30:25

Part 3: Awareness, education and care coordination

Elisabetta Bugianesi, University of Turin, Italy
30:25-43:44

Discussion

All
43:44-46:53

Take home message

Tom Hemming Karlsen, University of Oslo, Norway

 

Moderator

  
Tom H. Karlsen Dr Karlsen is currently professor of internal medicine at the University of Oslo. His research experience ranges from genetic epidemiology and applications of genomic technologies (via translational research) to clinical studies. He is leader of the Norwegian PSC research center at the Department of Transplantation Medicine and Research Institute of Internal Medicine. He is co-founder and former secretary (2010-2017) of the International PSC study group, has served as the coordinator of the Nordic Liver Transplant Registry from 2006-2014, served as Secretary General for European Association for the Study of the Liver (EASL) from 2017 to 2019 and is currently a board member of the Biomed Alliance in Europe. Dr. Karlsen served as co-chair of the EASL-Lancet Commission on Liver Disease in Europe.

Faculty

  
Rachel Pryke Dr Rachel Pryke is a part-time GP in Worcestershire with a special interest in obesity. She is RCGP Clinical Advisor on Nutrition who established the RCGP GPs with an Interest in Nutrition Group (GPING) in 2013 and, held a NICE Fellowship 2015-18. Dr. Pryke is also chair of the primary care section of the EASL Lancet Commission on Liver Disease across Europe, was a member of the Lancet Standing Commission on Liver Disease in UK and was member of the NICE NAFLD guideline development group and Quality Standard group. She runs primary care obesity training courses throughout the UK and has collaborated with WHO on a European primary care obesity training package.
Patrizia Carrieri Dr Patrizia Carrieri is a researcher in epidemiology and public health at the National Institute of Health and Medical Research (INSERM) at the SESSTIM in Marseille, France. She coordinates a line of research on access to prevention and care for people at risk of or living with a liver disease integrating community-based research methods. She is responsible for the public health section of the ANRS HEPAVIH cohorts of HIV and HCV co-infected patients and ANRS HEPATHER cohort of people with HBV or HCV infection. More recently, she has led research on barriers to access to care for people with alcohol use disorders, on novel therapeutic interventions to reduce stigma and other alcohol-related harms and on the needs and interventions for people with NAFLD/NASH.
Elisabetta Bugianesi Dr Bugianesi, is currently Professor of Gastroenterology and Scientific Director of the Dept of Medical Sciences at the University of Turin in Italy. She is an internationally acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-yearsexperience. Her contribution to the field includes, describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, and the involvement in several trials for the treatment of NAFLD/NASH.
Log in to post comments

EASL Studio S1 E2: The AASLD Liver Meeting

Description

This EASL Studio has been shining the spotlight on news straight from the AASLD Liver Meeting. Watch the transatlantic discussion on key emerging concepts and the presentations that kept our experts on the edge of their seats.

Time Title
00:00-04:12

Welcome and introductions

Aleksander Krag, Odense University Hospital, Denmark

Raymond T. Chung, Massachusetts General Hospital, USA
04:12-28:26

Topic 1: News with clinical impact – NASH/NAFLD drug development

Meena Bansal, Icahn School of Medicine at Mount Sinai, USA
28:26-47:34

Topic 2: News with clinical impact: Viral Hepatitis B - Novel drug development

Joseph Lim, Yale University School of Medicine, USA
47:34-50:31

Hot topics at ILC 2022

Aleksander Krag, Odense University Hospital, Denmark

 

Moderators

  
Aleksander Krag Aleksander Krag, MD, PhD, MBA, is Professor and Head of Hepatology and Director of Odense Liver Research Centre at Odense University Hospital. He is also Chair of Health Sciences at the Danish Institute of Advanced Studies (DIAS) at University of Southern Denmark, Associate editor at Danish Medical Journal and Editor in Chief at Medicin.dk. He holds leader positions in a number of research collaborations including being the director of the Fibrosis Fatty Liver and Steatohepatitis (FLASH) Research Centre Odense, and is involved in several international organisational activities. Research is his passion with a focus on liver fibrosis, complications to cirrhosis, alcoholic liver disease and microbiome.
Raymond Chung Dr Raymond Chung is Director of Hepatology and the Liver Center, Vice Chief of Gastroenterology and the Kevin and Polly Maroni Research Scholar at Massachusetts General Hospital. He is also Professor of Medicine at Harvard Medical School. He has been an internationally recognized leader in HCV virology, pathogenesis, and hepatocarcinogenesis. In addition, he has been an Associate Editor of Hepatology, Gastroenterology, and the Journal of Infectious Diseases, and is currently President of the American Association for the Study of Liver Diseases (AASLD).

Faculty

  
Meena Bansal Dr Bansal is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Secretary for AASLD, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis and NASH.
Joseph Lim Dr Lim is a Professor of Medicine and Vice-Chief of the Section of Digestive Diseases at Yale University, where he serves as Director of Clinical Hepatology and Associate Chief of Yale-New Haven Health System (YNHHS) Digestive Health. In his role at Yale Liver Center, he directs an active clinical trials program evaluating novel investigational agents for viral hepatitis and NASH. He serves on the AASLD CME Committee (Chair), Scientific Program Committee, and Viral Hepatitis Elimination Taskforce.
Log in to post comments

EASL Studio Special Edition: Highlights of Liver Cancer Summit 2022

Description

The highlights of EASL's Liver Cancer Summit 2022 -  What is practice changing right now and where are the current controversies?

How do our experts interprete the new data on Immunotherapy in HCC and CCA, and what to expect in 2022: Upcoming trials, New combinations, New biomarkers

Watch on-demand the session that was broadcast Friday 4 February 2022.

 

 

Moderator

  
Tom Luedde Tom Lüdde is Professor and Chair of the Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf (Germany). He was a visiting scientist at the Lineberger Cancer Centre (USA) and was appointed Professor at the University of Aachen. His main research interests are inflammation in metabolic liver disease and cancer and artificial intelligence and deep learning in gastrointestinal diseases and cancer. He is the recipient of the Ernst Jung Career Advancement Award and the Thannhauser Award from the German Association of Digestive Disease (DGVS).

Faculty

  
Bruno Sangro Prof. Bruno Sangro is Director of the Liver Unit and Co-Director of the HPB Oncology Area at Clínica Universidad de Navarra in Pamplona, Spain. He is also Professor of Internal Medicine and leads an active research group in the Spanish Network for Biomedical Research on Hepatic and Digestive Diseases (CIBEREHD), focused on therapeutic innovation in the field of liver cancer. He currently serves as Past President of the International Liver Cancer Association.
Tim Greten Dr Greten is co-chair of the Center of Excellence in Immunology, member of the Center for Advanced Preclinical Research oversight. In 2010 he joined CCR's Medical Oncology Branch as head of the Gastrointestinal Malignancy Section and was promoted as a tenured Senior Investigator in 2015 and Deputy Branch Chief in 2018. Dr. Greten has published more than 200 peer-reviewed papers on basic tumor immunology, translational research studies in hepatocellular carcinoma (HCC) as well as on clinical trials in different gastrointestinal malignancies, including HCC.
Log in to post comments
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Autoimmune sclerosing cholangitis & PSC: the spectrum of bile duct changes from childhood and through adult life

ERN Rare-Liver on-demand Webinar: Autoimmune sclerosing cholangitis & PSC: the spectrum of bile duct changes from childhood an...

On-demand Webinars
View
General Hepatology
Quiz: 63-year-old Irish lawyer with healthy appearance (bronzed skin) and a normal body mass index

Quiz: 63-year-old Irish lawyer with healthy appearance (bronzed skin) and a normal body mass index

Quiz
View
General Hepatology
EASL Studio Podcast S3 E5: JHEP Live: Stigma and alcohol

EASL Studio Podcast S3 E5: JHEP Live: Stigma and alcohol

EASL Studio
View
General Hepatology
EASL Studio Podcasts S3 E1: JHEP Live: Covid vaccination and associated autoimmune hepatitis

EASL Studio Podcasts S3 E1: JHEP Live: Covid vaccination and associated autoimmune hepatitis

Podcasts
View
Cirrhosis & Complications
EASL Studio Podcasts S3 E2: Liver transplantation for ACLF: Opportunities, challenges and pitfalls

EASL Studio Podcasts S3 E2: Liver transplantation for ACLF: Opportunities, challenges and pitfalls

Podcasts
View
Metabolism, Alcohol & Toxicity
EASL Studio Podcast S3 E4: Special Edition: Highlights of EASL NAFLD Summit 2022

EASL Studio Podcast S3 E4: Special Edition: Highlights of EASL NAFLD Summit 2022

Podcasts
View
COVID-19 and the liver
Quiz: A 46-year-old patient with severe COVID-19 survives due to intensive care with multiple drugs and prolonged artificial ventilation and extracorporeal membrane oxygenation

Quiz: A 46-year-old patient with severe COVID-19 survives due to intensive care with multiple drugs and prolonged artificial v...

Quiz
View
Viral Hepatitis
Quiz: A 24-year-old woman presents at week 20 of her pregnancy.

Quiz: A 24-year-old woman presents at week 20 of her pregnancy.

Quiz
View
Metabolism, Alcohol & Toxicity
Quiz: Fibrosis is the most important prognostic factor in NAFLD, correlating with liver-related outcomes and mortality.

Quiz: Fibrosis is the most important prognostic factor in NAFLD, correlating with liver-related outcomes and mortality.

Quiz
View
Displaying 361 - 372 of 441